Medical device company Hemovent GmbH reported on Monday the receipt of the CE marking for its MOBYBOX Runner Controller, to market the product throughout the heart and lung support market in the EU.
The company said the Runner is designed to slingshot clinicians into a new era of mobility and ease of use. The device is designed for Extracorporeal Life Support (ECLS) applications, including Extracorporeal CardioPulmonary Resuscitation (ECPR) to treat patients in cardiac arrest or profound circulatory shock.
Following the Runner EU regulatory approval, the company has created an entirely new solution for the extreme challenges of ECLS deployment in situations with unpredictable and severely restricted emergency environments, said Oliver Marseille, PhD, chief technology officer of Hemovent and a co-founder of CircuLite (Heartware International) prior to co-founding Hemovent.
In 2019, the company receive the CE mark for the MOBYBOX System with the Master Controller and is currently in preparing a post market clinical follow-up trial.
Viatris' generic iron sucrose injection gains US FDA approval
CorMedix to acquire Melinta Therapeutics in USD300m deal to expand infectious disease portfolio
US FDA approves Innovent's IND application for IBI3032 oral GLP-1R agonist
GEN and Sulfateq report positive Phase 1 data for SUL-238 in Alzheimer's
Philips launches ECG AI Marketplace to streamline cardiac diagnostics
AstraZeneca's Baxdrostat meets all endpoints in pivotal Phase III hypertension trial
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
EDX Medical and Spire Healthcare sign strategic diagnostic partnership agreement
Bayer and Broad Institute extend cardiovascular research alliance to advance precision therapies